Get the Stockscreener App
27.08
3.29%
-0.92
After Hours:
27.08
Alumis Inc stock is traded at $27.08, with a volume of 1.05M.
It is down -3.29% in the last 24 hours and up +2.58% over the past month.
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
See More
Previous Close:
$28.00
Open:
$27.79
24h Volume:
1.05M
Relative Volume:
0.80
Market Cap:
$3.45B
Revenue:
$8.40M
Net Income/Loss:
$-237.42M
P/E Ratio:
-14.09
EPS:
-1.9213
Net Cash Flow:
$-377.03M
1W Performance:
-3.22%
1M Performance:
+2.58%
6M Performance:
+4.15%
1Y Performance:
+597.94%
1-Day Range:
$26.72
$29.28
1-Week Range:
$26.72
$30.11
52-Week Range:
$3.75
$31.35
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis Inc
Sector
Industry
Phone
650-231-6625
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
27.08 | 3.57B | 8.40M | -237.42M | -377.03M | -1.9213 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Initiated | Raymond James | Strong Buy |
| Feb-25-26 | Initiated | Stifel | Buy |
| Jan-21-26 | Initiated | Chardan Capital Markets | Buy |
| Jul-25-25 | Initiated | Wells Fargo | Overweight |
| Jun-10-25 | Resumed | Guggenheim | Buy |
| Jan-30-25 | Initiated | Oppenheimer | Outperform |
| Oct-31-24 | Initiated | Robert W. Baird | Outperform |
| Oct-17-24 | Initiated | H.C. Wainwright | Buy |
| Jul-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-23-24 | Initiated | Guggenheim | Buy |
| Jul-23-24 | Initiated | Leerink Partners | Outperform |
| Jul-23-24 | Initiated | Morgan Stanley | Overweight |
View All
Alumis Inc Stock (ALMS) Latest News
BlackRock, Inc. (ALMS) reports 7.1M-share, 5.7% beneficial stake in Alumis - Stock Titan
Alumis Inc (ALMS) Balance Sheet - TradingKey
Alumis Inc (ALMS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Alumis Inc (ALMS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Alumis Inc (ALMS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Alumis Inc (ALMS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ALMS|Alumis Inc|Price:28.000|Chg%:-0.300 - TradingKey
Alumis Inc. Revenue Breakdown – NASDAQ:ALMS - TradingView
Alumis Inc (ALMS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
(ALMS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Alumis Inc. (ALMS) Receives a Rating Update from a Top Analyst - The Globe and Mail
Stifel Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $44 - Moomoo
Stifel reiterates Alumis stock Buy rating ahead of lupus data By Investing.com - Investing.com South Africa
Stifel reiterates Alumis stock Buy rating ahead of lupus data - Investing.com
Alumis chief legal officer Sanam Pangali sells $140,000 stock - Investing.com
Alumis chief legal officer Sanam Pangali sells $140,000 stock By Investing.com - Investing.com South Africa
Form 4 Alumis Inc For: 8 July By Investing.com - Investing.com Nigeria
Alumis (NASDAQ: ALMS) legal chief sells 5,000 shares after option exercise - Stock Titan
Alumis Inc stock hits all-time high at 30.67 USD By Investing.com - Investing.com Nigeria
Alumis Inc stock hits all-time high at 30.67 USD - Investing.com
Cantor Fitzgerald reiterates Alumis stock Overweight rating ahead of data By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Alumis stock Overweight rating ahead of data - Investing.com
Alumis Inc. (ALMS) Surges 6.78% as Stock Tests Key Resistance ZoneEarly Entry Signals - dars.gov.et
[144] ALUMIS INC. SEC Filing - Stock Titan
Price to sales forward of Alumis Inc. – NASDAQ:ALMS - TradingView
Price to book forward of Alumis Inc. – NASDAQ:ALMS - TradingView
Form 4 Alumis Inc For: 2 July By Investing.com - Investing.com Nigeria
Alumis (ALMS) director Lynn Tetrault receives RSU and stock option awards - Stock Titan
Director at ALUMIS (NASDAQ: ALMS) receives RSU and option grants - Stock Titan
[Form 4] ALUMIS INC. Insider Trading Activity - Stock Titan
Alumis (ALMS) director awarded new RSUs and stock options - Stock Titan
Alumis (ALMS) director Akkaraju receives RSUs, options and reports fund stakes - Stock Titan
Form 13D/A Alumis Inc. For: 2 July By Investing.com - Investing.com Nigeria
Alumis (ALMS) major holder keeps 15.1M-share stake as ownership hits 12.3% - Stock Titan
[8-K] ALUMIS INC. Reports Material Event - Stock Titan
Alumis Inc. Q1 2026 Earnings: Narrowing Losses as Key Pipeline Milestones ApproachEarnings Volatility Report - dars.gov.et
Stifel and Guggenheim Stay Bullish on Alumis (ALMS) - Insider Monkey
Enterprise value to EBITDA forward of Alumis Inc. – NASDAQ:ALMS - TradingView
Wells Fargo Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $51 - Moomoo
Enterprise value to revenue forward of Alumis Inc. – NASDAQ:ALMS - TradingView
Alumis Inc. (ALMS) Q1 2026 Earnings: Narrower Loss Beats Estimates, Stock Climbs 2.8%ROIC Trend Report - dars.gov.et
Alumis Inc.(NasdaqGS: ALMS) added to Russell 2500 Growth Benchmark - marketscreener.com
ALMS Forecast — Price Target — Prediction for 2027 - TradingView
Alumis Inc.(NasdaqGS: ALMS) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Alumis Unveils Breakthrough TYK2 Inhibitors: Leading Clinical Results in Psoriasis and Lupus, $180B+ Market Opportunity by 2030 318 – Minichart - Minichart
Alumis Inc.(NasdaqGS: ALMS) dropped from Russell 2000 Value Benchmark - marketscreener.com
Alumis updates corporate presentation highlighting envudeucitinib Phase 3 wins, SLE and NDA timing - TradingView
Alumis (NASDAQ: ALMS) posts updated June 2026 corporate presentation - Stock Titan
Alumis Inc.(NasdaqGS: ALMS) added to Russell 2000 Growth Benchmark - marketscreener.com
Alumis (ALMS) Is Up 7.3% After Russell Reclassifies It Into Growth Indices What’s Changed - simplywall.st
Alumis Inc Stock (ALMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):